Isomorphic Labs president Max Jaderberg plans to move drug discovery from physical trial and error into computer simulations. The Alphabet-backed company uses predictive artificial intelligence to tackle clinical failure rates, focusing on oncology and inflammation.
FireBrief
FireBrief